• Invo Fertility revenue rose 18% to USD 2.2 million in the three months ended June 30, 2026.
• Cost of services increased 24% to USD 1.4 million, driven by the addition of the Indiana Clinic.
• Selling, general and administrative expenses fell to USD 1.9 million from USD 2.2 million on lower professional services costs.
• Gain on remeasurement totaled USD 2.5 million, reflecting the Alabama note receivable and HRCFG acquisition remeasurement.
• For the six months ended June 30, 2026, net loss narrowed to USD 4.7 million; cash was USD 3.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invo Fertility Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038528), on August 14, 2026, and is solely responsible for the information contained therein.